在新诊断或复发的扩散性大B细胞淋巴瘤的老年患者中,减少强度的无环环素化学免疫疗法
1Division of Hematology/Oncology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
患有扩散性大B细胞淋巴瘤 (DLBCL) 的老年患者不适合标准治疗,对无环素治疗方案 (R2-COP) 反应良好. 这种化疗免疫治疗方法为这个脆弱的患者群体提供了耐受性良好和有效的选择.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床医学 临床医学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是最常见的非霍奇金淋巴瘤 (NHL).
- 标准的基于 antracycline 的化疗免疫疗法可以达到 ~ 50% 的治愈率,但老年,不适合的患者对其耐受性不佳.
- 在老年,脆弱的DLBCL患者中,由于治疗不耐受,低于最佳的结果仍然存在.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
相关概念视频
Treatment Resistant Cancers
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
